CN105106172A - Medicine of erdosteine composition capsule for treating airway inflammation - Google Patents
Medicine of erdosteine composition capsule for treating airway inflammation Download PDFInfo
- Publication number
- CN105106172A CN105106172A CN201510633018.XA CN201510633018A CN105106172A CN 105106172 A CN105106172 A CN 105106172A CN 201510633018 A CN201510633018 A CN 201510633018A CN 105106172 A CN105106172 A CN 105106172A
- Authority
- CN
- China
- Prior art keywords
- erdosteine
- weight portion
- medicine
- composition capsule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses medicine of an erdosteine composition capsule for treating airway inflammation, and belongs to the technical field of medicine. The erdosteine composition capsule is prepared from erdosteine, starch, nordihydroguaiaretic acid, 95-percent ethanol, polyvidone K30 and talcum. The erdosteine is a novel crystal form compound; an X-ray powder diffraction pattern obtained through Cu-Ka ray measurement is shown as a Figure 1; the medicine belongs to the erdosteine different from that reported in the prior art. Experiments show that the erdosteine novel crystal form compound has better solubility and higher stability; the prepared capsule has high dissolution rate and good stability, and is very suitable for clinic application.
Description
Technical field
The invention belongs to medical art, relate to a kind of medicine erdosteine composition capsule for the treatment of respiratory inflammation.
Background technology
Expectorant is the product of respiratory inflammation, can stimulate respiratory mucosa, causes cough and asthma, and can increase the weight of to infect.When acute/chronic bronchitis or chronic lung diseases respiratory failure, spend height as patient's thick sputum or form expectorant bolt, can clogs airways and cause suffocating.Therefore, use sticky expectorant regulator, make patient's phlegm dissolving, thinning, viscosity reduces, and accelerate respiratory mucosa ciliary movement, improve transport function, tool is of great significance.
This is smooth etc. for the sticky expectorant regulator of current listing such as bromhexine, mesna, carboxylic first, all has sticky expectorant regulating action in various degree, but its pharmacology or there are some defects clinically.Sulfydryl free in molecular structure can adsorb gastrointestinal tract mucin, gastrointestinal tract local damage can be produced after oral, side effect is larger, the antibacterial activity of penicillin, cephalosporins, erythromycin, tetracycline etc. can be weakened, unsuitable drug combination, not high to the improvement effect of some respiration parameter as expectorant viscosity etc.
Erdosteine is a kind of prodrug, with the sulfydryl closed of non-free in its structure, to local mucin inactive, after oral through metabolism produce three containing free sulfhydryl groups metabolite and play pharmacological action, thus oral rear without obvious gastrointestinal side effect.Experiment proves; erdosteine cylinder metabolism-ure can make mucinous disulfide bonds in bronchial secretion; and change secretions composition and rheological property; reduce sputum viscosity; improve downtrod respiratory function; this product energy scavenging free radicals, the oxidation deactivation that available protecting a1-antitrypsin brings out from cigarette, dirt, prevents the damage to elastance of lung albumen and neutrophilic granulocyte.This product obviously can also increase IgA/ albumin, lactoferrin/albuminous ratio, weakens local inflammation, strengthens and improves the osmosis of antibiotic to bronchial mucosa, be conducive to the treatment of the various inflammation of respiratory tract.External clinical clinical studies show: with like product as acetylcysteine, this is smooth for carboxylic first, ambroxol etc. compares, this product has good curative effect to acute/chronic bronchitis, more effective to the improvement of some respiratory function parameter, there is not drug accumulation in heavy dose of administration, Liver and kidney function moderate obstacle to this product characteristics of pharmacokinetics without obvious change.
The water solublity of erdosteine is poor, effective bioavailability in human body is low, and medicine in vivo infiltration rate usually determined by the speed dissolved, medicine in solid preparation is before being absorbed, have to pass through disintegrate and dissolve the process then transferring solution to, if medicine not easily discharges from preparation or the dissolution velocity of medicine is very slow, then the infiltration rate of said preparation Chinese medicine or degree just likely have problems.
The approach of existing solution erdosteine poorly water-soluble mainly comprises change dosage form, as CN101606931B is made into dispersible tablet, although above-mentioned preparation improves the water solublity of medicine to a certain extent, also there is many defects.Therefore, the erdosteine compound that a kind of performance improvement is provided is necessary.
The present inventor starts with from the research of erdosteine solid chemical material existence, a kind of erdosteine compound crystal has been prepared through a large amount of tests, find through overtesting, this erdosteine crystal compound has good dissolubility and higher stability, the capsule dissolubility made is high, good stability, is very applicable to clinical practice.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of medicine erdosteine composition capsule for the treatment of respiratory inflammation.
In order to complete object of the present invention, the technical scheme of employing is:
Treat a medicine erdosteine composition capsule for respiratory inflammation, described composition capsule is made up of erdosteine, starch, nor-pair of hydrogen guaiaretic acid, 95% ethanol, PVP K30, Pulvis Talci; Described erdosteine is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
Preferably, described composition capsule is made up of the erdosteine of 1.5 weight portions, the starch of 1.5-1.7 weight portion, nor-pair of hydrogen guaiaretic acid of 0.08-0.12 weight portion, 95% ethanol of 0.7-0.9 weight portion, the PVP K30 of 0.04-0.06 weight portion, the Pulvis Talci of 0.03-0.05 weight portion.
Preferably, described composition capsule is made up of the erdosteine of 1.5 weight portions, the starch of 1.6 weight portions, nor-pair of hydrogen guaiaretic acid of 0.1 weight portion, 95% ethanol of 0.8 weight portion, the PVP K30 of 0.05 weight portion, the Pulvis Talci of 0.04 weight portion.
Preferably, the preparation method of described composition capsule comprises the following steps:
(1) supplementary material process: sieve erdosteine, nor-pair of hydrogen guaiaretic acid 80 orders;
(2) weigh: weigh according to prescription;
(3) binding agent preparation: the PVP K30 of recipe quantity is dissolved in 95% ethanol, stand-by;
(4) granulate: erdosteine, starch, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, are dry mixed 10 minutes; Add the binding agent wet mixing cutting 2-3min prepared, 18 orders granulation soft material processed;
(5) dry: to be evenly split on the drip pan of baking oven by the wet granular of granulation gained, set temperature 55-65 DEG C, dry total time is 2.5-3.0 hour, material 20 order granulate after dry;
(6) mix: granule after granulate and Pulvis Talci are dropped into three-dimensional motion mixer, premixing speed 10 revs/min, incorporation time 15 minutes are set;
(7) capsule fill: carry out fill according to after the theoretical loading amount scope of total mixed gained material cubage;
(8) pack.
Preferably, the preparation method of described erdosteine crystal comprises the following steps:
(1) get erdosteine crude drug, add in the deionized water of 50 DEG C, the volumetric usage of deionized water is 5 times of the quality of erdosteine;
(2) whole dissolving is stirred to;
(3) add activated carbon decolorizing, filter, obtain settled solution;
(4) move in pressure vessel by settled solution, being controlled by the pressure in pressure vessel at 1.0Mpa and drip the isopropyl alcohol of 5 DEG C under the condition stirred, speed of agitator is 35rmp, and the volumetric usage of isopropyl alcohol is 5 times of the volume of deionized water;
(5) bleed off pressure after being added dropwise to complete, with the speed of 10 DEG C/min, solution is cooled to-5 DEG C, leave standstill 2h, filter, washing, drying under reduced pressure, obtains erdosteine crystal.
The present invention is by the precise controlling to crystallization condition, prepare a kind of novel crystal forms unlike the prior art, the X-ray powder diffraction pattern of this erdosteine crystal unlike the prior art, simultaneously due to the ins and outs of this crystal formation, find through test, this erdosteine crystal compound has good dissolubility and higher stability, and the capsule dissolution made is high, good stability, is very applicable to clinical practice.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the erdosteine crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of erdosteine crystal
(1) get erdosteine crude drug, add in the deionized water of 50 DEG C, the volumetric usage of deionized water is 5 times of the quality of erdosteine;
(2) whole dissolving is stirred to;
(3) add activated carbon decolorizing, filter, obtain settled solution;
(4) move in pressure vessel by settled solution, being controlled by the pressure in pressure vessel at 1.0Mpa and drip the isopropyl alcohol of 5 DEG C under the condition stirred, speed of agitator is 35rmp, and the volumetric usage of isopropyl alcohol is 5 times of the volume of deionized water;
(5) bleed off pressure after being added dropwise to complete, with the speed of 10 DEG C/min, solution is cooled to-5 DEG C, leave standstill 2h, filter, washing, drying under reduced pressure, obtains erdosteine crystal.
The X-ray powder diffraction pattern that the erdosteine crystal prepared uses the measurement of Cu-K alpha ray to obtain as shown in Figure 1.
embodiment 2:the preparation of erdosteine capsule
Prescription: erdosteine crystal-form compound, the starch of 1.5 weight portions, nor-pair of hydrogen guaiaretic acid of 0.08 weight portion, 95% ethanol of 0.7 weight portion, the PVP K30 of 0.04 weight portion, the Pulvis Talci of 0.03 weight portion that the embodiment 1 of 1.5 weight portions is obtained.
Preparation method:
(1) supplementary material process: sieve erdosteine, nor-pair of hydrogen guaiaretic acid 80 orders;
(2) weigh: weigh according to prescription;
(3) binding agent preparation: the PVP K30 of recipe quantity is dissolved in 95% ethanol, stand-by;
(4) granulate: erdosteine, starch, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, are dry mixed 10 minutes; Add the binding agent wet mixing cutting 2-3min prepared, 18 orders granulation soft material processed;
(5) dry: to be evenly split on the drip pan of baking oven by the wet granular of granulation gained, set temperature 55-65 DEG C, dry total time is 2.5-3.0 hour, material 20 order granulate after dry;
(6) mix: granule after granulate and Pulvis Talci are dropped into three-dimensional motion mixer, premixing speed 10 revs/min, incorporation time 15 minutes are set;
(7) capsule fill: carry out fill according to after the theoretical loading amount scope of total mixed gained material cubage;
(8) pack.
embodiment 3:the preparation of erdosteine capsule
Prescription: erdosteine crystal-form compound, the starch of 1.6 weight portions, nor-pair of hydrogen guaiaretic acid of 0.1 weight portion, 95% ethanol of 0.8 weight portion, the PVP K30 of 0.05 weight portion, the Pulvis Talci of 0.04 weight portion that the embodiment 1 of 1.5 weight portions is obtained.
Preparation method:
(1) supplementary material process: sieve erdosteine, nor-pair of hydrogen guaiaretic acid 80 orders;
(2) weigh: weigh according to prescription;
(3) binding agent preparation: the PVP K30 of recipe quantity is dissolved in 95% ethanol, stand-by;
(4) granulate: erdosteine, starch, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, are dry mixed 10 minutes; Add the binding agent wet mixing cutting 2-3min prepared, 18 orders granulation soft material processed;
(5) dry: to be evenly split on the drip pan of baking oven by the wet granular of granulation gained, set temperature 55-65 DEG C, dry total time is 2.5-3.0 hour, material 20 order granulate after dry;
(6) mix: granule after granulate and Pulvis Talci are dropped into three-dimensional motion mixer, premixing speed 10 revs/min, incorporation time 15 minutes are set;
(7) capsule fill: carry out fill according to after the theoretical loading amount scope of total mixed gained material cubage;
(8) pack.
embodiment 4:the preparation of erdosteine capsule
Prescription: erdosteine crystal-form compound, the starch of 1.7 weight portions, nor-pair of hydrogen guaiaretic acid of 0.12 weight portion, 95% ethanol of 0.9 weight portion, the PVP K30 of 0.06 weight portion, the Pulvis Talci of 0.05 weight portion that the embodiment 1 of 1.5 weight portions is obtained.
Preparation method:
(1) supplementary material process: sieve erdosteine, nor-pair of hydrogen guaiaretic acid 80 orders;
(2) weigh: weigh according to prescription;
(3) binding agent preparation: the PVP K30 of recipe quantity is dissolved in 95% ethanol, stand-by;
(4) granulate: erdosteine, starch, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, are dry mixed 10 minutes; Add the binding agent wet mixing cutting 2-3min prepared, 18 orders granulation soft material processed;
(5) dry: to be evenly split on the drip pan of baking oven by the wet granular of granulation gained, set temperature 55-65 DEG C, dry total time is 2.5-3.0 hour, material 20 order granulate after dry;
(6) mix: granule after granulate and Pulvis Talci are dropped into three-dimensional motion mixer, premixing speed 10 revs/min, incorporation time 15 minutes are set;
(7) capsule fill: carry out fill according to after the theoretical loading amount scope of total mixed gained material cubage;
(8) pack.
experimental example 1:
This experimental example is the stability test of product of the present invention
1, accelerated test
Three batches of products of Example 1, in temperature be 40 ± 2 DEG C, relative humidity be the condition of 75 ± 5% under place 6 months, respectively at 0,1,2,3,6 the end of month sampling once, measure, in table 1 by high spot reviews project.
Table 1 accelerated test result (temperature 40 ± 2 DEG C, relative humidity 75% ± 5%)
Result shows, this product temperature be 40 ± 2 DEG C, relative humidity be 75 ± 5% conditions under place 6 months, its related substances is low, and each index has no significant change, and this product quality stability is good.
2, long term test
Example 1 product, in temperature be 25 DEG C, relative humidity be 60% ± 10% place, respectively at 0,3,6,9,12,18,24 the end of month sampling and measuring.Measure character, content and related substance according to pertinent regulations under " quality standard " item, record result (the results are shown in following table 2), and compare with criticizing to record for 0 month.
Table 2 long-term test results (temperature 25 ± 2 DEG C, relative humidity 60% ± 5%)
Shown by long-term test results: erdosteine compound of the present invention is 25 ± 2 DEG C in temperature, relative humidity is place under the condition of 60% ± 5% to stablize for 24 months, and indices is without significant change.
experimental example 2:
The water solublity that this experimental example carries out the 3 batch sample erdosteine compounds testing the embodiment of the present invention 1 is tested, compared with commercially available erdosteine.Specific experiment method is: in the low capacity bottle of constant temperature jacket, add appropriate distilled water, erdosteine is added to no longer dissolving at 25 DEG C, start magnetic stirrer, Keep agitation under constant temperature, in experimentation, system is in the state of two-phase coexistent all the time, after 70 minutes system liquid phase in the concentration of erdosteine be dissolubility at this temperature.Carry out sample analysis after 2 hours, get the close meansigma methods of adjacent two times result as measured value of experiment, before sampling, in order to make solid-liquid fully be separated, after stopping stirring, not molten erdosteine is deposited to the bottom of low capacity bottle, extract a small amount of upper clear supernate with syringe, filter with the filter of 0.45 micron, sample thief from filtrate, the content of erdosteine is measured, specifically in table 3 by HPLC.
The water solublity of erdosteine compound of the present invention under table 3 room temperature
From upper table analysis, the water solublity of erdosteine compound provided by the invention improves greatly.
Claims (5)
1. treat a medicine erdosteine composition capsule for respiratory inflammation, it is characterized in that: described composition capsule is made up of erdosteine, starch, nor-pair of hydrogen guaiaretic acid, 95% ethanol, PVP K30, Pulvis Talci; Described erdosteine is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. the medicine erdosteine composition capsule for the treatment of respiratory inflammation according to claim 1, is characterized in that: described composition capsule is made up of the erdosteine of 1.5 weight portions, the starch of 1.5-1.7 weight portion, nor-pair of hydrogen guaiaretic acid of 0.08-0.12 weight portion, 95% ethanol of 0.7-0.9 weight portion, the PVP K30 of 0.04-0.06 weight portion, the Pulvis Talci of 0.03-0.05 weight portion.
3. the medicine erdosteine composition capsule for the treatment of respiratory inflammation according to claim 2, is characterized in that: described composition capsule is made up of the erdosteine of 1.5 weight portions, the starch of 1.6 weight portions, nor-pair of hydrogen guaiaretic acid of 0.1 weight portion, 95% ethanol of 0.8 weight portion, the PVP K30 of 0.05 weight portion, the Pulvis Talci of 0.04 weight portion.
4. the medicine erdosteine composition capsule of the treatment respiratory inflammation according to any one of claim 1-3, it is characterized in that, the preparation method of described composition capsule comprises the following steps:
(1) supplementary material process: sieve erdosteine, nor-pair of hydrogen guaiaretic acid 80 orders;
(2) weigh: weigh according to prescription;
(3) binding agent preparation: the PVP K30 of recipe quantity is dissolved in 95% ethanol, stand-by;
(4) granulate: erdosteine, starch, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, are dry mixed 10 minutes; Add the binding agent wet mixing cutting 2-3min prepared, 18 orders granulation soft material processed;
(5) dry: to be evenly split on the drip pan of baking oven by the wet granular of granulation gained, set temperature 55-65 DEG C, dry total time is 2.5-3.0 hour, material 20 order granulate after dry;
(6) mix: granule after granulate and Pulvis Talci are dropped into three-dimensional motion mixer, premixing speed 10 revs/min, incorporation time 15 minutes are set;
(7) capsule fill: carry out fill according to after the theoretical loading amount scope of total mixed gained material cubage;
(8) pack.
5. the medicine erdosteine composition capsule for the treatment of respiratory inflammation according to claim 1, it is characterized in that, the preparation method of the crystal of described erdosteine comprises the following steps:
(1) get erdosteine crude drug, add in the deionized water of 50 DEG C, the volumetric usage of deionized water is 5 times of the quality of erdosteine;
(2) whole dissolving is stirred to;
(3) add activated carbon decolorizing, filter, obtain settled solution;
(4) move in pressure vessel by settled solution, being controlled by the pressure in pressure vessel at 1.0Mpa and drip the isopropyl alcohol of 5 DEG C under the condition stirred, speed of agitator is 35rmp, and the volumetric usage of isopropyl alcohol is 5 times of the volume of deionized water;
(5) bleed off pressure after being added dropwise to complete, with the speed of 10 DEG C/min, solution is cooled to-5 DEG C, leave standstill 2h, filter, washing, drying under reduced pressure, obtains erdosteine crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510633018.XA CN105106172A (en) | 2015-09-30 | 2015-09-30 | Medicine of erdosteine composition capsule for treating airway inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510633018.XA CN105106172A (en) | 2015-09-30 | 2015-09-30 | Medicine of erdosteine composition capsule for treating airway inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106172A true CN105106172A (en) | 2015-12-02 |
Family
ID=54654460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510633018.XA Withdrawn CN105106172A (en) | 2015-09-30 | 2015-09-30 | Medicine of erdosteine composition capsule for treating airway inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106172A (en) |
-
2015
- 2015-09-30 CN CN201510633018.XA patent/CN105106172A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112716903B (en) | Amlodipine dry suspension and preparation method thereof | |
| WO2021042278A1 (en) | Multi-unit sustained-release acipimox pellet tablet and preparation method therefor | |
| CN107233331A (en) | A kind of berberine granula subtilis and preparation method thereof | |
| TWI747906B (en) | A new crystal form of dapagliflozin, its preparation method and use thereof | |
| CN104788421B (en) | A kind of erdosteine compound treating respiratory inflammation and preparation method thereof | |
| CN108685870A (en) | Jamaicin and its can forming salt enteric-coated micro-pill, its prepare and application | |
| CN104825472A (en) | Fever/pain relieving and anti-inflammatory pharmaceutical composition and preparation method thereof | |
| CN105343028A (en) | Medicine composition with norfloxacin and method for preparing medicine composition | |
| CN107412198A (en) | Duloxetine hydrochloride enteric slow release granule and preparation method thereof | |
| CN109925287A (en) | A kind of Pyrochep and preparation method thereof | |
| CN104873495A (en) | Erdosteine composition for treating respiratory tract inflammation | |
| CN103191065A (en) | Celecoxib new formulation and preparation method thereof | |
| CN105106172A (en) | Medicine of erdosteine composition capsule for treating airway inflammation | |
| CN105193750A (en) | Medicine erdosteine composition tablet for treating airway inflammation | |
| CN105232473A (en) | Pharmaceutical erdosteine composite granules for treating respiratory tract infection | |
| CN105640895B (en) | A kind of cefadroxil granular preparation and preparation method thereof | |
| CN108283628A (en) | A kind of anticancer drug microcapsule formulation and preparation method thereof | |
| CN106176642B (en) | A kind of Disket and preparation method thereof for treating respiratory disease | |
| CN104983693A (en) | Medicine erdosteine composition granules for treating respiratory tract infection | |
| CN105078901A (en) | Erdosteine pharmaceutical composition dry suspension for treating diseases of respiratory system | |
| CN105232445A (en) | Erdosteine composition dry suspension for treating respiratory system disease | |
| CN106749174A (en) | A kind of sitafloxacin dihydrate crystal formation, preparation method and combinations thereof tablet | |
| CN105055348A (en) | Medicinal erdosteine composition tablet for treating respiratory tract inflammation and preparation method of tablet | |
| CN107536808B (en) | Miriplatin freeze-dried preparation and preparation method thereof | |
| CN107569473A (en) | A kind of Sustained Release Ambroxol Hydrochloride Capsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151202 |
|
| WW01 | Invention patent application withdrawn after publication |